ViiV Healthcare Presents Phase III Data at AIDS 2018 from Landmark GEMINI Studies Showing Two-Drug Regimen of Dolutegravir and Lamivudine Has Similar Efficacy to a Three-Drug Regimen in Treatment Naï

Go back to ViiV Healthcare Presents Phase III Data at AIDS 2018 from Landmark GEMINI Studies Showing Two-Drug Regimen of Dolutegravir and Lamivudine Has Similar Efficacy to a Three-Drug Regimen in Treatment Naï
GLAXOSMITHKLINE PLC (NYSE: GSK) Delayed: 51.08 --0 (-0%)
Previous Close $51.08    52 Week High $45.58 
Open $51.08    52 Week Low $37.82 
Day High $51.08    P/E N/A 
Day Low $51.08    EPS $0.00 
Volume 4,597       

GLAXOSMITHKLINE PLC (NYSE: GSK) Delayed: 51.08 --0 (-0%)
Previous Close $51.08    52 Week High $45.58 
Open $51.08    52 Week Low $37.82 
Day High $51.08    P/E N/A 
Day Low $51.08    EPS $0.00 
Volume 4,597       

Pfizer Inc. (NYSE: PFE) Delayed: 27.74 --0 (-0%)
Previous Close $27.74    52 Week High $37.39 
Open $27.74    52 Week Low $28.25 
Day High $27.74    P/E 16.81 
Day Low $27.74    EPS $1.65 
Volume 22,096